Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Jan 2 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BRAVEHEART who wrote (390)	11/19/1998 2:59:00 PM
From: Dr. John M. de Castro	of 1494

Jeffrey, Good question regarding the Orphan Drug status. I don't know the answer. I'm also not sure as to exactly what are the rules for that designation. I'll have to check. AIDS Dementia is very common. So, I'm not sure whether it would qualify as an Orphan Drug. Your point that memantine could be used as a prophylactic for AIDS Dementia is also a good one. I'd think that it would be prudent for an HIV positive individual to take memantine along with the cocktail drugs. I doubt that NTII will get this on the label from the FDA since they are not testing it as a preventative. But, the physicians caring for the HIV positive patients may well choose to use it that way. In any case, whether it is used for prevention or only for those diagnosed with dementia, memantine will have to be taken for a long period of time by a large number of individuals. This could make it a cash cow for NTII. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next